These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 8378409)

  • 1. Effects of moclobemide, a new generation reversible Mao-A inhibitor, in a novel animal model of depression.
    Moreau JL; Jenck F; Martin JR; Mortas P; Haefely W
    Pharmacopsychiatry; 1993 Jan; 26(1):30-3. PubMed ID: 8378409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolcapone: a potential new antidepressant detected in a novel animal model of depression.
    Moreau JL; Borgulya J; Jenck F; Martin JR
    Behav Pharmacol; 1994 Jun; 5(3):344-350. PubMed ID: 11224284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curative effects of the atypical antidepressant mianserin in the chronic mild stress-induced anhedonia model of depression.
    Moreau JL; Bourson A; Jenck F; Martin JR; Mortas P
    J Psychiatry Neurosci; 1994 Jan; 19(1):51-6. PubMed ID: 8148366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic mild stress-induced anhedonia model of depression; sleep abnormalities and curative effects of electroshock treatment.
    Moreau JL; Scherschlicht R; Jenck F; Martin JR
    Behav Pharmacol; 1995 Nov; 6(7):682-687. PubMed ID: 11224370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of stress-induced deficit in aggression by monoamine oxidase inhibitors.
    Ossowska G; Klenk-Majewska B; Danilczuk Z; Wróbel A; Zebrowska-Lupina I
    Pol J Pharmacol; 1999; 51(5):391-7. PubMed ID: 10817539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
    Roth M; Guelfi JD
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():18-24. PubMed ID: 1394027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moclobemide in patients with dementia and depression.
    Amrein R; Martin JR; Cameron AM
    Adv Neurol; 1999; 80():509-19. PubMed ID: 10410765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of benzamide derivatives on convulsions induced by the toxic action of oxygen in rats].
    Gol'dina OA; Tepliakov VG; Demurov EA; Koloskov IuB; Zagorevskiĭ VA
    Biull Eksp Biol Med; 1987 Oct; 104(10):469-71. PubMed ID: 3676473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP; Tsoi WF
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression.
    Weinstock M; Poltyrev T; Bejar C; Youdim MB
    Psychopharmacology (Berl); 2002 Mar; 160(3):318-24. PubMed ID: 11889501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F; Wolfersdorf M
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
    Ebert D; Demling J
    Pharmacopsychiatry; 1991 Nov; 24(6):229-31. PubMed ID: 1687486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moclobemide for depression.
    Drug Ther Bull; 1994 Jan; 32(1):6-8. PubMed ID: 7635005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings).
    Stefanis CN; Alevizos B; Markianos M; Hatzimanolis J
    J Neural Transm Suppl; 1988; 26():87-95. PubMed ID: 2452231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M; Keller HH; Kettler R
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
    Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M
    J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.